- Previous Close
19.86 - Open
18.94 - Bid 18.97 x --
- Ask 18.98 x --
- Day's Range
18.93 - 20.30 - 52 Week Range
14.81 - 25.20 - Volume
6,342,886 - Avg. Volume
3,332,323 - Market Cap (intraday)
4.413B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
379.60 - EPS (TTM)
0.05 - Earnings Date --
- Forward Dividend & Yield 0.15 (0.74%)
- Ex-Dividend Date Oct 17, 2024
- 1y Target Est
--
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, manufacture, and sale of in-vitro diagnostic products China and internationally. Its products portfolio includes molecular diagnostic products, such as PCR system, nucleic acid extraction and purification instrument, and sample release reagent; blood gas analyzer; immuno diagnosis, including chemiluminescence immunoassay, fluorescence immunity, and immunoquantitative analyzer; and automatic coagulation analyzer. The company also provides emergency and critical illness information solutions, including software, hardware, and certification consulting services; and third-party medical inspection services. It offers products in the areas of cardiovascular and cerebrovascular diseases, infectious diseases, kidney diseases, diabetes, infectious diseases, prenatal and postnatal care, health examination, thyroid, hormones, blood gas, coagulation, drug metabolism, pathogen detection, etc. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
www.mdeasydiagnosis.comRecent News: 002932.SZ
View MorePerformance Overview: 002932.SZ
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002932.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002932.SZ
View MoreValuation Measures
Market Cap
4.74B
Enterprise Value
4.21B
Trailing P/E
407.40
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.27
Price/Book (mrq)
0.80
Enterprise Value/Revenue
12.05
Enterprise Value/EBITDA
310.07
Financial Highlights
Profitability and Income Statement
Profit Margin
3.03%
Return on Assets (ttm)
-1.46%
Return on Equity (ttm)
-0.82%
Revenue (ttm)
349.23M
Net Income Avi to Common (ttm)
10.56M
Diluted EPS (ttm)
0.05
Balance Sheet and Cash Flow
Total Cash (mrq)
557.71M
Total Debt/Equity (mrq)
0.46%
Levered Free Cash Flow (ttm)
-128.37M